Scholarlink

Background <p>Periorbital complications from hyaluronic acid (HA) fillers are common due to the region’s unique anatomy. Hyaluronidase is widely used for management, but dosing remains empirical with no standardized protocol. This study aimed to assess the safety and efficacy of a high-dose, single-session hyaluronidase approach for treating such complications.</p> Methods <p>A retrospective study was conducted on 54 patients presenting with periorbital HA-related complications between August 2020 and May 2024. Four main types of complications were identified: persistent edema, tear trough bulging, under-correction, and subcutaneous nodules. The average interval from the first HA injection to presentation was 25.8 months (range 1.5–72 months). Injection points were determined through visual inspection and palpation, marked at the most prominent areas, and spaced approximately 7–10&#xa0;mm apart. A vertical bolus injection technique was used to administer 30–90 IU (0.1–0.3&#xa0;mL) of hyaluronidase per point, totaling 150–600 IU per lower eyelid.</p> Results <p>The mean follow-up was 52.9 days (range 14–474 days). All patients responded successfully to one session of high-dose hyaluronidase. The mean dose per lower eyelid was 350.3 IU. No cases required retreatment. Nineteen patients (35.2%) achieved satisfactory outcomes without further intervention, while the remaining 35 (64.8%) underwent subsequent lower eyelid blepharoplasty.</p> Conclusion <p>High-dose, single-session hyaluronidase injection is a safe, effective, and efficient approach for treating a broad range of HA-related periorbital complications, even in complex cases involving multiple previous treatments or long filler retention time.</p> Level of Evidence IV <p> This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors <a href="http://www.springer.com/00266">www.springer.com/00266</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Single-Session High-Dose Hyaluronidase for Managing Periorbital Hyaluronic Acid Filler Complications

  • 期刊论文

  • 发表日期：

    2025年10月27日

查看全文
  • Jianwu Chen,
  • Fuguang Zhang,
  • Changhong Li,
  • Yuzhi Wang,
  • Qi Li,
  • Xuejun Weng,
  • Guang Peng

摘要

Background

Periorbital complications from hyaluronic acid (HA) fillers are common due to the region’s unique anatomy. Hyaluronidase is widely used for management, but dosing remains empirical with no standardized protocol. This study aimed to assess the safety and efficacy of a high-dose, single-session hyaluronidase approach for treating such complications.

Methods

A retrospective study was conducted on 54 patients presenting with periorbital HA-related complications between August 2020 and May 2024. Four main types of complications were identified: persistent edema, tear trough bulging, under-correction, and subcutaneous nodules. The average interval from the first HA injection to presentation was 25.8 months (range 1.5–72 months). Injection points were determined through visual inspection and palpation, marked at the most prominent areas, and spaced approximately 7–10 mm apart. A vertical bolus injection technique was used to administer 30–90 IU (0.1–0.3 mL) of hyaluronidase per point, totaling 150–600 IU per lower eyelid.

Results

The mean follow-up was 52.9 days (range 14–474 days). All patients responded successfully to one session of high-dose hyaluronidase. The mean dose per lower eyelid was 350.3 IU. No cases required retreatment. Nineteen patients (35.2%) achieved satisfactory outcomes without further intervention, while the remaining 35 (64.8%) underwent subsequent lower eyelid blepharoplasty.

Conclusion

High-dose, single-session hyaluronidase injection is a safe, effective, and efficient approach for treating a broad range of HA-related periorbital complications, even in complex cases involving multiple previous treatments or long filler retention time.

Level of Evidence IV

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.